About

Travecta Therapeutics is an emerging biotech company developing a platform that leverages our proprietary knowledge of the MFSD2A Transport for the targeted delivery of therapeutic agents to the brain and eye. Our platform and know-how allow us to identify and categorize small molecules for enabling their transport across the blood-brain barrier (BBB) and blood-retina barrier (BRB). Travecta partners with pharmaceutical companies to apply our platform and assist them in overcoming the challenges associated with delivering drugs across the BBB and BRB. Our internal program is focusing on the development of molecules that treat diseases of the central nervous system and the eye. Travecta Therapeutics was founded by experienced scientific leaders from Duke-NUS and backed by TKS1, a healthcare and life science focused VC fund formed by the partnership between SPRIM Ventures and Tikehau Capital. The company has offices in Philadelphia, PA and Singapore.